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Dear Editor,
New daily persistent headache (NDPH) was first described
by Vanast [1] in 1986 as a benign form of chronic daily
headache (CDH). Vanast described NDPH as a headache
that would improve without therapy, but as most headache
specialists know, NDPH can be one of the most refractory
forms of CDH to treatment. The diagnostic criteria for
NDPH based on the last edition of the International
Headache Society (IHS) Classification of Headache Dis-
orders [2] is as follows: headache for[3 months, daily and
unremitting from onset, with at least two of the following
pain characteristics: bilateral location, pressing/tightening
quality, mild or moderate intensity, not aggravated by
routine physical activity. Also both of the following: no
more than one of photophobia, phonophobia, or mild
nausea, and neither moderate nor severe nausea nor vom-
iting; finally, not attributed to another disorder.
The prevalence of CDH from population-based studies
in Asia, Europe, and the US is about 4% [3]. NDPH is
rarely stratified from the data in epidemiologic studies
focusing on CDH. Bigal et al. [4] found 10.8% of 638
patients with CDH in a headache specialty clinic had
NDPH. Koenig et al. [5] found that 13% of a pediatric
CDH population from selected pediatric headache specialty
clinics had NDPH and Castillo et al. [6] found a prevalence
of 0.1% of NDPH in 2,252 subjects in Spain with an
overall prevalence of 4.7% for CDH. Rozen [7] published
the first study demonstrating effective treatment of NDPH
in five patients with gabapentin or topiramate.
I present the case of a 67-year-old man with NDPH that
has been completely responsive to botulinum toxin type A
for 1 year. He reported the onset of headache in June of
2006. He reported the headache began in the occipital area
bilaterally and radiated to the vertex. He reported the
duration to be constant, and described the pain as sharp at
times, also dull, achy, and pressure like. He reported no
known triggers and denied photophobia and phonophobia.
He rated the pain a 6/10 on the severity scale most days.
Physical examination and testing of this patient failed to
reveal any secondary cause for the headache and I diag-
nosed him with NDPH.
In August 2007, the patient received his first set of
injections of botulinum toxin type A, 100 units in the
following muscles: glabellar, frontalis, temporalis, suboc-
cipital medial and lateral, semispinalis, splenius capitus,
and trapezius. When he returned in November of 2007 for
the second set of injections, he reported becoming head-
ache free 4 days after the first set of injections and
remaining that way for 8 weeks. He reported the headache
returned was unchanged and remained daily. He received a
second set of injections, 100 units, in the same locations
and returned to the office in January 2008. At that time, he
reported becoming headache free again within 4 days of
treatment and remaining that way until approximately
10 days prior to that appointment. He also reported less
severity of pain although the headache had returned. He
received his third round of botulinum toxin type A when he
returned to the office in May 2008. He reported being
completely headache free for 10 weeks and again with less
severity, reporting a level of 3/10 for his headache when it
returned.
Therapy of primary headache disorders or pain disorders
with botulinum toxin A is relatively new. Analysis of the
available studies and experience with botulinum toxin A in
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the treatment of primary headache disorders shows that a
general efficacy of this therapy cannot be postulated to
date. This is due to conflicting results in multiple studies
[8]; however, in clinical practice wider series of patients
with CDH received substantial benefits from botulinum
toxin type A [9].
To my knowledge, this is the first case report of the
demonstrated efficacy of botulinum toxin type A in the
treatment of NDPH. In conclusion, botulinum toxin A may
be a sufficient therapy for specific subgroups of patients
with primary headache disorders. In the case of NDPH, a
well designed and controlled pilot study using botulinum
toxin A is needed for validation of my finding in this
report. This can be performed in a blinded double dummy
study, which is very difficult to design. It is important,
however, to test the validity of this therapy in such a
refractory headache disorder as NDPH.
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